01 November 2006
Antibiotic resistance of pediatric isolates of Streptococcus pneumoniae in a Saudi Arabian hospital from 1999 to 2004Jaffar A. Al-Tawfiq
Med Sci Monit 2006; 12(11): CR471-475 :: ID: 462702
Background: This study describes the resistance pattern of Streptococcus pneumoniae isolates obtained from pediatric patients in a Saudi Arabian hospital.
Material/Methods: This is a retrospective analysis of the antibiotic resistance of S. pneumoniae isolates (n=141) obtained from children in a Saudi Arabian hospital 1999–2004. Clinical data and antibiotic sensitivity were retrieved from microbiology data and analyzed.
Results: Of the total isolates of S. pneumoniae, 57.6% were susceptible to penicillin, 28.8% intermediately susceptible, and 13.7% were resistant organisms. Over the study period, high-level penicillin resistance of S. pneumoniae was 0% in 1999, 23% in 2001, and 3.4% in 2004. Intermediate penicillin resistance was 21% in 1999, 41% in 2001, and 27.6% in 2004. The resistance rates to other antibiotics were as follows: erythromycin 33.4%, tetracycline 30%, trimethoprim sulfamethoxazole 40%, and clindamycin 21.6%. Children less than 2 years of age showed a higher rate of intermediately penicillin-susceptible isolates (41.9% versus 22.7%, P=0.0.02). They also had higher rates of resistance to tetracycline (42.4% versus 25%, P=0.03), trimethoprim-sulfamethoxazole (54% versus 33.8%, P=0.02), and clindamycin (33% versus 17%, P=0.04). All tested isolates were susceptibility to ceftriaxone and vancomycin.
Conclusions: The overall high-level penicillin resistance of S. pneumonaie from 1999–2004 was 13.7%. The percentage of intermediately penicillin-susceptible organisms was higher in the age group under 2 years of age (41.9%) than in patients 2 years of age or older (22.7%).
Keywords: Streptococcus pneumoniae - metabolism, Streptococcal Infections - drug therapy, Saudi Arabia, Pneumococcal Infections - drug therapy, Penicillins - pharmacology, Penicillin Resistance, Microbial Sensitivity Tests, Anti-Bacterial Agents - pharmacology, Drug Resistance, Microbial, Child, Preschool, Child, Adolescent
01 May 2023 : EditorialEditorial: Twenty Years On from Sequencing the Human Genome, Personalized/Precision Oncology Prepares to Meet the Challenges of Checkpoint Inhibitor Therapy
Med Sci Monit 2023; 29:e940911
31 May 2023 : Review articlePrevalence, Diagnosis, and Management of Eclampsia and the Need for Improved Maternal Care: A Review
Med Sci Monit In Press; DOI: 10.12659/MSM.939919
30 May 2023 : Clinical ResearchA Case-Control Study of Cognitive Function in Patients with End-Stage Renal Disease Before and After Hemodi...
Med Sci Monit In Press; DOI: 10.12659/MSM.940409
30 May 2023 : Review articleA Review of the Role of the Zebrafish (Danio reiro) in Preclinical and Clinical Models of Biomarker Identif...
Med Sci Monit In Press; DOI: 10.12659/MSM.940550
30 May 2023 : Database AnalysisThe COVID-19 Crisis and the Incidence of Alcohol-Related Deaths in Poland
Med Sci Monit In Press; DOI: 10.12659/MSM.940904
Most Viewed Current Articles
13 Nov 2021 : Clinical ResearchAcceptance of COVID-19 Vaccination and Its Associated Factors Among Cancer Patients Attending the Oncology ...
Med Sci Monit 2021; 27:e932788
30 Dec 2021 : Clinical ResearchRetrospective Study of Outcomes and Hospitalization Rates of Patients in Italy with a Confirmed Diagnosis o...
Med Sci Monit 2021; 27:e935379
08 Mar 2022 : Review articleA Review of the Potential Roles of Antioxidant and Anti-Inflammatory Pharmacological Approaches for the Man...
Med Sci Monit 2022; 28:e936292
01 Jan 2022 : EditorialEditorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...
Med Sci Monit 2022; 28:e935952